Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CS DiagnosticsCSDX Return-on-Tangible-Equity is 315.15% as of Dec. 2025, which is 53% above its 10-year median of 205.80. The stock has 1 warning sign investors should review. Among 758 Medical Devices & Instruments companies, CS Diagnostics ranks better than 94.06% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. CS Diagnostics's annualized net income for the quarter that ended in Dec. 2025 was $0.16 Mil. CS Diagnostics's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $0.05 Mil. Therefore, CS Diagnostics's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 315.15%.
The historical rank and industry rank for CS Diagnostics's Return-on-Tangible-Equity or its related term are showing as below:
CSDX'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 120.93 Med: 205.8 Max: 205.8
Current: 120.93
During the past 7 years, CS Diagnostics's highest Return-on-Tangible-Equity was 205.80%. The lowest was 120.93%. And the median was 205.80%.
CSDX's Return-on-Tangible-Equity is ranked better than 94.06% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.055
vs CSDX: 120.93
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
CS Diagnostics Return-on-Tangible-Equity Related Terms
CS Diagnostics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for CS Diagnostics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSDX vs NMTC, IRIX, LFWD: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, CS Diagnostics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CS Diagnostics Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CS Diagnostics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where CS Diagnostics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 315.15% mean?
CS Diagnostics (CSDX) has a Return-on-Tangible-Equity of 315.15% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on CS Diagnostics and its competitors. This is 53% above median its historical median of 205.80. Over the past decade, CS Diagnostics' Return-on-Tangible-Equity has ranged from 120.93 to 205.80. According to the industry distribution chart, CS Diagnostics ranks #45 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 5.9%.
Is CS Diagnostics' Return-on-Tangible-Equity too high?
CS Diagnostics' current Return-on-Tangible-Equity of 315.15% is 53% above median its 10-year median of 205.80. Over the past 10 years, this metric has ranged from a low of 120.93 to a high of 205.80. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.06. CS Diagnostics' value of 315.15% is 7671.9% above this industry median. Based on the distribution chart, CS Diagnostics ranks #45 out of 758 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does CS Diagnostics' Return-on-Tangible-Equity compare to NMTC and IRIX?
According to the Medical Devices & Instruments industry distribution chart, CS Diagnostics ranks #45 out of 758 companies for Return-on-Tangible-Equity. This places CS Diagnostics in the top 6% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.06. CS Diagnostics' value of 315.15% is 7671.9% above this benchmark. Historically, CS Diagnostics' own Return-on-Tangible-Equity has ranged from 120.93 to 205.80 over the past decade. While the company's 10-year median is 205.80 vs. the industry median of 4.06, CS Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.06, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CS Diagnostics's current Return-on-Tangible-Equity of 315.15% is 7671.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on CS Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CS Diagnostics's current Return-on-Tangible-Equity is 315.15%, which is 53% above median its own 10-year median of 205.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CS Diagnostics stock overvalued right now?
CS Diagnostics (CSDX) has a current Return-on-Tangible-Equity of 315.15%. The current Return-on-Tangible-Equity is 315.15%, which is 53% above median its 10-year median of 205.80 and 7671.9% above the Medical Devices & Instruments industry median of 4.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For CS Diagnostics (CSDX), the current Return-on-Tangible-Equity is 315.15% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CS Diagnostics Corp is a United States based Corporation, its focus is on improving therapy results and reducing side effects. In addition, it offers international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, it develops its own products with the aim of maximizing patient benefit.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSDX has been successfully added to your 
